A Phase 2 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Arena Pharmaceuticals. Completed at 127 sites in 21 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-11-26.
Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 8th largest by enrollment, is the only one that started in 2016, is one of 6 in phase 2, and was the 2nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Pfizer · Sites in United States, Japan, Poland and 2 more countries
Ages 12–17
Sir Run Run Shaw Hospital
Ages 18–100
By country, each count listing its studies:
etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2016.
This study's enrollment of 118 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 195 across the 12 interventional studies. Of the 7 that completed or were terminated, 7 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Arena Pharmaceuticals, one of the names counted as Pfizer. Under that name alone:
Arena Pharmaceuticals is the lead sponsor of 17 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
42 studies in Colitis, Ulcerative by Pfizer: 3 open now, 7 under way, 2 of them phase 3. Of 32 finished, 26 (81%) have results posted.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 13th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2016, is one of 12 in phase 2, and was the 12th registered.
Pfizer’s Colitis, Ulcerative studies by the year they started, since 2005.
1 of the studies testing etrasimod in Colitis, Ulcerative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07782242Sir Run Run Shaw HospitalComaprison of Efficacy and Safety Between Etrasimod vs Mesalazine in Chinese Adults With Active UC | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing etrasimod in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 42 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Etrasimod
Drug: Placebo
Also known as: APD334
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
A TEAE was defined as any adverse event (AE) that occurred after the first dose of study drug in the APD334-005 (NCT02536404) study, including any AE that started in Study APD334-003 (NCT02447302) and was ongoing, worsened, or ended in Study APD334-005. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events.
Time frame: Up to Week 48 (up to 30 days following discontinuation of the study drug)
Proportion of Participants Who Achieved Clinical Response
A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
Time frame: Week 46 (extension study APD334-005)
Proportion of Participants Who Achieved Clinical Response at Week 12 in APD334-003 and Maintained Clinical Response at Week 46 in APD334-005
A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
Time frame: Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)
Proportion of Participants Who Achieved Clinical Remission
A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
Time frame: Week 46 (extension study APD334-005)
Proportion of Participants Who Achieved Clinical Remission at Week 12 in APD334-003 and Also Maintained Clinical Remission at Week 46 in APD334-005
A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
Time frame: Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)
| Milestone | Etrasimod 2 mg | Placebo |
|---|---|---|
| Started | 112 | 6 |
| Completed | 92 | 5 |
| Not completed | 20 | 1 |
| Withdrew: Adverse event | 5 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Physician decision | 10 | 0 |
| Withdrew: Sponsor decision | 1 | 0 |
A TEAE was defined as any adverse event (AE) that occurred after the first dose of study drug in the APD334-005 (NCT02536404) study, including any AE that started in Study APD334-003 (NCT02447302) and was ongoing, worsened, or ended in Study APD334-005. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events.
| Participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| TEAEs | 67 | 5 |
| Treatment-emergent SAEs | 7 | 0 |
A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Proportion of Participants Who Achieved Clinical Response | 78.6 (69.9 to 85.7) | 75.0 (24.9 to 98.7) |
A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Proportion of Participants Who Achieved Clinical Response at Week 12 in APD334-003 and Maintained Clinical Response at Week 46 in APD334-005 | 39.3 (30.3 to 48.8) | 50.0 (9.8 to 90.2) |
A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Proportion of Participants Who Achieved Clinical Remission | 39.3 (30.3 to 48.8) | 25.0 (1.3 to 75.1) |
A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
| Percentage of participants | Etrasimod 2 mg | Placebo |
|---|---|---|
| Proportion of Participants Who Achieved Clinical Remission at Week 12 in APD334-003 and Also Maintained Clinical Remission at Week 46 in APD334-005 | 14.3 (8.5 to 22.1) | 0 (0.0 to 52.7) |
Collected over Up to Week 48 (up to 30 days following discontinuation of the study drug). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Etrasimod 2 mg | 0/112 (0%) | 7/112 (6.3%) | 66/112 (58.9%) |
| Placebo | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Event | Etrasimod 2 mg | Placebo |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 3/112 | 0/6 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 2/112 | 0/6 |
| Atrial fibrillationCardiac disorders | 1/112 | 0/6 |
| Large intestine perforationGastrointestinal disorders | 1/112 | 0/6 |
| PancreatitisGastrointestinal disorders | 1/112 | 0/6 |
| Proctitis ulcerativeGastrointestinal disorders | 1/112 | 0/6 |
| GastroenteritisInfections and infestations | 1/112 | 0/6 |
| Fine motor skill dysfunctionNervous system disorders | 1/112 | 0/6 |
| Transient ischaemic attackNervous system disorders | 1/112 | 0/6 |
| Cystitis haemorrhagicRenal and urinary disorders | 1/112 | 0/6 |
| Event | Etrasimod 2 mg | Placebo |
|---|---|---|
| Back painMusculoskeletal and connective tissue disorders | 4/112 | 2/6 |
| NasopharyngitisInfections and infestations | 6/112 | 2/6 |
| Faecal calprotectin increasedInvestigations | 3/112 | 1/6 |
| Carpal tunnel syndromeNervous system disorders | 1/112 | 1/6 |
| VitreousEye disorders | 0/112 | 1/6 |
| Colitis ulcerativeGastrointestinal disorders | 16/112 | 1/6 |
| NauseaGastrointestinal disorders | 5/112 | 1/6 |
| Dental cariesGastrointestinal disorders | 0/112 | 1/6 |
| GastritisGastrointestinal disorders | 0/112 | 1/6 |
| GlossodyniaGastrointestinal disorders | 0/112 | 1/6 |
Baseline data are reported for members of the Safety Population, comprised of all participants who received study medication in the extension study APD334-005 (NCT02536404).
| Age, Continuous(Years) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| Mean | 43.7 ± 13.25 | 50.2 ± 13.93 | 44.0 ± 13.30 |
| Sex: Female, Male(Participants) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| Female | 44 | 3 | 47 |
| Male | 68 | 3 | 71 |
| Ethnicity (NIH/OMB)(Participants) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 0 | 4 |
| Not Hispanic or Latino | 108 | 6 | 114 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Etrasimod 2 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 0 | 4 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 0 | 1 |
| White | 104 | 6 | 110 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 |
Showing the first 100 of 127 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2016 to primary completion in Nov 2018, 33 months.
Results were first posted in Nov 2021, 3 years after primary completion. A results delay was requested in Oct 2019.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 33 months is above that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod